Arbutus Biopharma Corporation Announces FDA Lifts Clinical Hold on IND Application for AB-101

On October 22, 2026, Arbutus Biopharma said the FDA lifted the clinical hold on the Investigational New Drug application for AB-101, its oral PD-L1 inhibitor. The hold’s removal clears a regulatory obstacle to the program’s development; the provided article text is truncated before further details.